These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 34565066)

  • 21. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A; Singh M; Acker WW; Kamboj S; Sporn D; Stapleton D; Kaluski E
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):82-90. PubMed ID: 31306367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
    Sindet-Pedersen C; Lamberts M; Staerk L; Nissen Bonde A; Berger JS; Pallisgaard JL; Lock Hansen M; Torp-Pedersen C; Gislason GH; Olesen JB
    J Am Coll Cardiol; 2018 Oct; 72(15):1790-1800. PubMed ID: 30286922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
    Lacoste JL; Hansen CL
    Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry.
    Boivin-Proulx LA; Deneault-Marchand A; Matteau A; Mansour S; Gobeil F; Camm JA; Fox KAA; Potter BJ
    Clin Cardiol; 2020 Mar; 43(3):216-221. PubMed ID: 31850592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
    Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Gibson CM; Alexander JH
    JAMA Cardiol; 2019 Aug; 4(8):747-755. PubMed ID: 31215979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
    Darius H
    Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified.
    Andrade JG; Deyell MW; Wong GC; Macle L
    Can J Cardiol; 2018 Nov; 34(11):1426-1436. PubMed ID: 30404748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany.
    Zeymer U; Toelg R; Wienbergen H; Hobbach HP; Cuneo A; Bekeredjian R; Ritter O; Hailer B; Hertting K; Hennersdorf M; Scholtz W; Lanzer P; Mudra H; Schwefer M; Schwimmbeck PL; Liebetrau C; Thiele H; Claas C; Riemer T; Zahn R
    Herz; 2023 Mar; 48(2):134-140. PubMed ID: 35243515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct Oral Anticoagulants Would Be Best Choice for Atrial Fibrillation Patients After Coronary Stenting: Retrospective Study in a Japanese Population.
    Koiwaya H; Watanabe N; Kuriyama N; Shibata Y
    Kurume Med J; 2023 Jul; 68(2):97-106. PubMed ID: 37100602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting.
    Buccheri S; Angiolillo DJ; Capodanno D
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719891688. PubMed ID: 31814532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis.
    Vitolo M; Javed S; Capodanno D; Rubboli A; Boriani G; Lip GYH
    Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):587-600. PubMed ID: 32772746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.